【恒瑞医药:卓托奇拜单抗注射液上市许可申请获受理】恒瑞医药公告称,公司子公司广东恒瑞医药有限公司收到国家药监局下发的《受理通知书》,卓托奇拜单抗注射液的药品上市许可申请获受理。该药品拟定用于治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎,为公司自主研发的靶向人IL-4Rα的重组人源化单克隆抗体。截至目前,该项目累计研发投入约3.86亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.